Vaxcyte Stock Plunges 37.43% on Disappointing Phase 2 Results

On March 31, 2025, Vaxcyte's stock price plummeted by 37.43% in pre-market trading, marking a significant decline for the biotechnology company.

Vaxcyte's recent Phase 2 study results have been a major factor in the stock's decline. The company announced topline results from its Phase 2 dose-finding study of VAX-24, which did not meet expectations, leading to a sharp drop in investor confidence.

In response to the disappointing study results, Vaxcyte has scheduled a webcast and conference call to present the findings in detail. This move is aimed at providing transparency and addressing investor concerns, although it remains to be seen whether it will be enough to stabilize the stock price.